Gene · 4017
Papers2,536
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 2,536
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| NADPH oxidase 1/4 dual inhibition impairs transforming growth factor-beta protumorigenic effects in cholangiocarcinoma cancer-associated fibroblasts. | Signal Transduct Target Ther | 2025 | 40820091 | PubTator, text mining | PubMed |
| To explore the potential of LOXL2 as a biomarker in glioma and construct a genomic integrated clinical prognostic model. | Front Oncol | 2025 | 40756111 | PubTator, text mining | PubMed |
| From laboratory to clinic: a precise treatment strategy of mesenchymal stem cells-derived exosomes pretreated by simulating disease microenvironment. | Front Immunol | 2025 | 40746527 | PubTator, text mining | PubMed |
| Dihydroartemisinin Suppresses LOXL2-Mediated Glycerophospholipid Metabolic Reprogramming to Induce Cuproptosis in Colorectal Cancer Cells. | J Biochem Mol Toxicol | 2025 | 40746272 | PubTator, text mining | PubMed |
| Enhanced THBS2 promotes collagen synthesis and inflammatory secretome of fibroblasts in idiopathic pulmonary fibrosis. | Sci Rep | 2025 | 40676074 | PubTator, text mining | PubMed |
| Preoperative serum LOXL2 levels are elevated in patients with pulmonary hypertension undergoing mitral valve surgery in a prospective observational cohort study. | J Appl Physiol (1985) | 2025 | 40637430 | PubTator, text mining | PubMed |
| ER stress genes (COL1A1, LOXL2, VWF) predicts IKK-16 as a Candidate therapeutic target for colitis-related inflammation and fibrosis suppression. | Front Immunol | 2025 | 40607383 | PubTator, text mining | PubMed |
| The small molecule LOXL2 inhibitor SNT-5382 reduces cardiac fibrosis and achieves strong clinical target engagement. | Sci Rep | 2025 | 40596021 | PubTator, text mining | PubMed |
| Cuproptosis: a novel therapeutic mechanism in lung cancer. | Cancer Cell Int | 2025 | 40555995 | PubTator, text mining | PubMed |
| A novel mesothelioma molecular classification based on malignant cell differentiation. | Cancer Cell Int | 2025 | 40555979 | PubTator, text mining | PubMed |
| SMARCB1 orchestrates cellular plasticity and oncogenic pathways in typical and chondroid chordomas. | Sci Rep | 2025 | 40481032 | PubTator, text mining | PubMed |
| Salivary Extracellular Vesicles in Detection of Head and Neck Cancers: A Systematic Review. | Int J Nanomedicine | 2025 | 40452788 | PubTator, text mining | PubMed |
| LOXL2 reduces susceptibility to PARP inhibitors by promoting super-enhancer-regulated DNA damage repair in high-grade serous ovarian cancer. | Oncogene | 2025 | 40447755 | PubTator, text mining | PubMed |
| MMA-induced LOXL2+ PSCs promote linear ECM alignment in the aging pancreas leading to pancreatic cancer progression. | Cell Death Dis | 2025 | 40425551 | PubTator, text mining | PubMed |
| In vitro 3D modeling of colorectal cancer: the pivotal role of the extracellular matrix, stroma and immune modulation. | Front Genet | 2025 | 40376304 | PubTator, text mining | PubMed |
| Challenges of in vitro modelling of liver fibrosis. | Front Cell Dev Biol | 2025 | 40371390 | PubTator, text mining | PubMed |
| Editorial: Cardiovascular immunometabolism - a complex interplay between the immune system and metabolism in the heart. | Front Endocrinol (Lausanne) | 2025 | 40370780 | PubTator, text mining | PubMed |
| Editorial on the Themed Issue in Honor of Carlos Gutiérrez Merino: Forty Years of Research Excellence in the Field of Membrane Proteins and Bioenergetics. | Molecules | 2025 | 40333596 | PubTator, text mining | PubMed |
| The increased matrix stiffness caused by LOXL2 activates Piezo1 channels to promote the migration and invasion of cervical cancer cells. | Discov Oncol | 2025 | 40304808 | PubTator, text mining | PubMed |
| Gelatin methacryloyl bioinks for bioprinting nasal cartilage: Balancing mechanical integrity and extracellular matrix formation. | Int J Biol Macromol | 2025 | 40294687 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4017/papers?page=6